undamentalytics Newsletter
Sign in

Prime Medicine, Inc. income statement

In fiscal 2025, Prime Medicine, Inc. reported revenue of $4.6m, up 55.3% on the year before, operating income of −$208m (a -4498.1% margin) and net income of −$201m, or −$1.35 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue500035
Research and development37187148155161
General and administrative31430435052
Operating income−1−84−117−205−202−208
Income tax2−0−1−000
Net income−3−165−122−198−196−201
Diluted EPS−$0.38−$14.19−$4.19−$2.18−$1.65−$1.35
Diluted shares (average)13m13m34m91m119m149m
EBITDA−1−84−114−200−196−201

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: OCGN vs PRMEPRME vs TRDABOLT vs PRME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Prime Medicine, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prime Medicine, Inc.